10 October 2018
The European Medicines Agency (EMA) and the European Commission’s Directorate-General for Health and Food Safety (DG SANTE) have published a joint action plan to support the development of medicines for children in Europe.
09 October 2018
The global biologics market was worth $221 billion in 2017 and is essentially segmented into monoclonal antibodies, therapeutic proteins and vaccines. Biologics are very large complex molecules manufactured in a living system such as microorganisms, animal cells or plant cells. They are produced using the recombinant DNA technology and are composed of sugars, proteins, nucleic acids or a combination of these substances.
08 October 2018
Prospective entry into the market of the Eurasian Economic Union (EAEU) of foreign medicinal products registered according to the national procedures of the EAEU States were discussed by the Member of the Board – Minister in charge of Technical Regulation of the Eurasian Economic Commission (EEC) Viktor Nazarenko and the Deputy Minister of Public Health of the Republic of Cuba, Dr. Marcia Cobas Ruiz on September 18 at the EEC venue.
31 October 2018
Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.
30 October 2018
Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.
29 October 2018
The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.
26 October 2018
Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.